1,720,977 research outputs found
Erythrodermic psoriasis successfully and rapidly treated with brodalumab: report of two cases
No full textErythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering ≥90% of the body surface area (BSA). The management of EP is challenging: no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy. However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been ustekinumab, whereas infliximab might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of brodalumab (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here we report the first two cases of efficacy and safety of brodalumab in real-life cases of EP. This article is protected by copyright. All rights reserved
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data
No full textIntroduction: Psoriasis is a very common chronic inflammatory skin disease affecting up to 3% of the general population with 75% of the psoriasis subjects being affected by a mild form of disease. Hence, topical therapy is the most frequent employed treatment in psoriasis also because it can be easily combined with systemic therapy. In this context, calcipotriol/betamethasone dipropionate (Cal/BD) fixed-dose association represents the first-line treatment due to its efficacy and once-daily application. Different Cal/BD formulations, such as ointment, gel (topical suspension) and aerosol foam, are approved by US Food and Drug Administration.
Areas covered: For this review, relevant English literature (trials, real life studies, case series and reviews) regarding Cal/BD different formulations efficacy in psoriasis was searched for through to January 28, 2020. The following database were consulted: PubMed, Embase, The Cochrane Library, Google Scholar, EBSCO, and clinicaltrials.gov.
Expert opinion: Cal/BD formulations are efficacious treatment for psoriasis. Cal/BD aerosol foam shows a higher efficacy compared to Cal/BD ointment or gel formulations, appearing as a game changer in psoriasis therapy not only for mild disease but also for moderate psoriasis as well as in selected severe cases in combination with systemic treatments
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study
No full textUp until now, real-life experiences on the efficacy of risankizumab in patients who had previously failed anti-IL17, anti-IL12/23 or anti-IL23 inhibitor are not reported. We carried out a single-centre, retrospective study, to evaluate the efficacy, safety and tolerability of patients under risankizumab who previously failed anti-IL17, anti-IL12/23 or anti-IL23 inhibitors in a real-life setting. A total of 8 patients were enrolled (4 men and 4 women, mean age 45.8 ± 14.3 years). Five of them (62.5%) had received ustekinumab, 7 (87.5%) at least one anti-IL17, and only one (12.5%) patient guselkumab. Secukinumab had been used in 5 (62.5%) cases, and ixekizumab in 4 (50.0%). Baseline mean PASI and BSA were 11.9 ± 5.5, and 22.9 ± 13.1, respectively, and 3.3±1.7 and 7.5 ± 5 (P<0.001 and P<0.01) at week 16. Mean baseline NAPSI (18.0 ± 8.5) reduced to 7 ± 1.4 at week 16. Palmo-plantar and scalp area showed a reduction of 67.5% and 99.9% at week 16, respectively. No AEs was reported. Real-life preliminary data show risankizumab as a promising therapeutic option in patients who failed anti-IL-17, anti-IL12/23 and even the other anti-IL-23 counterpart, guselkumab. This article is protected by copyright. All rights reserved
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study
No full textRecent major research advancements have significantly expanded our understanding of psoriasis' pathophysiology, resulting in the development of highly-effective, targeted therapies. Guselkumab is the first interleukin (IL)-23-inhibitor approved for the treatment of moderate-to-severe-psoriasis, providing a new therapeutical option for psoriasis. The aim of our study was to evaluate the efficacy of guselkumab in psoriatic patients who previously failed anti-IL-12/23 and/or anti-IL-17
Erythrasmoid pityriasis versicolor with exclusive involvement of the pubis and inguinal region: report of two cases.
No full textBiologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II
No full textPsoriasis awareness among general population: preliminary results of an online survey
No full textBackground: Psoriasis represents one of the most common skin diseases in Italy, with a prevalence of 2.9%. It has been defined as a noncommunicable disease, due to its high burden and impact on patients' quality of life.
Aims: The aim of our observational study was to assess the actual knowledge and perception of psoriasis in Italian population by administering an online 10-question survey to a representative sample general population.
Methods: An online 10-question survey was administered to a representative sample general population from September 2019 to December 2019. A representative sample of general population (age ≥ 18 years) was enrolled by promoting the online survey through multiple means of communication such as social sites (Facebook, Instagram) or delivering a questionnaire link in public spaces (outpatient clinic, pharmacy). All results were then collected and analyzed in graphs by the Google form platform.
Results: 151 individuals participated in the survey. Results showed that 7.3% (n=11) of general population were not familiar with the term psoriasis; 4.6% (n=7) thought to psoriasis as an infectious disease and 6% (n=9) thought that psoriasis was contagious. Interestingly, 39.1% (n=59) of participants have never heard about targeted/biologic therapy.
Limitations: Our study is limited by the small sample size as well as lack of data regarding sex, age and education level of the study participant.
Conclusions: There is still lack of knowledge of psoriasis among general population, representing an obstacle for patients' everyday activities and quality of life. Future studies to investigate the details of this impaired knowledge and new psoriasis campaign on large scale should fill this gap are required
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
No full textIL‐23‐inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and risankizumab in real world practice. An Italian single‐center retrospective cohort study enrolling moderate‐to‐severe psoriasis patients from September 1, 2018 and December 31, 2020 was performed to indirectly compare guselkumab and risankizumab efficacy and safety. Sixty eight patients were included (36 received guselkumab and 32 risankizumab). The groups were comparable for all analyzed characteristics, except for mean psoriasis duration (p < 0.01) which was higher for guselkumab. In guselkumab group, mean PASI reduced from 16.1 ± 6.4 (baseline) 2.1 ± 0.9 (week‐28) (p < 0.001) up to 0.9 ± 0.8 (week‐44) (p < 0.001). In risankizumab group mean PASI decreased from 13.5 ± 4.9 (baseline) 1.9 ± 0.8 (p < 0.001), (week‐28) (p < 0.001) up to 0.9 ± 0.4 (week‐40) (p < 0.001). No significant difference in mean PASI and BSA were observed between the treatments. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported in both groups. Guselkumab and risankizumab showed favorable efficacy and safety profile, being comparable in terms of PASI90 and PASI100 responses as well as in AEs frequency and discontinuation rates
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
No full textObjectives: We aimed to evaluate the effectiveness, safety and tolerability of guselkumab in a real-life setting.Methods: A prospective, observational, single-center, real-life study including patients under guselkumab treatment from October 2018 to January 2020 was conducted.Results: Twenty-three patients with moderate-to-severe psoriasis were enrolled and twenty-two continued the treatment until week 44. One patient discontinued for increase in liver enzymes. At baseline, mean PASI score was 15.1 ± 6.1, which reduced up to 3.2 ± 1.9 at week 12 (p < 0.001) and 0.8 ± 0.7 at week 44 (p < 0.001). BSA reduced from 36.4 ± 13.6 at baseline, to 8.3 ± 7.4 at week 12 (p < 0.001), up to 2.2 ± 1.4 at week 44 (p < 0.001). A total of 4 patients (17.4%) experienced mild blood tests alterations and 6 subjects (26%) experienced potential adverse events (AEs). No AEs required guselkumab discontinuation. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported.Conclusions: Patients under guselkumab therapy reach an optimal clinical response, even in a real-life and long-term setting
- …
